Delia-Maria Nicoară,Alexandra-Cristina Scutca,Niculina Mang,Iulius Juganaru,Andrei-Ioan Munteanu,Luiza Vitan,Otilia Mărginean
Central precocious puberty in Prader-Willi syndrome: a narrative review
Prader-Willi syndrome,precocious puberty,endocrine,genetic,metabolic
Prader-Willi syndrome (PWS, OMIM176270) is a rare genetic disorder with recognizable dysmorphic features and multisystemic consequences such as endocrine, neurocognitive and metabolic ones. Although most patients with Prader-Willi syndrome exhibit hypogonadotropic hypogonadism, there is variability regarding sexual maturation, with precocious puberty occurring in rare cases. Our aim is to elaborate a thorough review of Prader-Willi patients with central precocious puberty, in order to raise awareness of such cases and to enhance our knowledge regarding the diagnosis and prompt treatment of this particular PWS patients.
Central precocious puberty in Prader-Willi syndrome: a narrative review

Prader-Willi syndrome (PWS, OMIM176270) is a rare genetic disorder with recognizable dysmorphic features and multisystemic consequences such as endocrine, neurocognitive and metabolic ones. Although most patients with Prader-Willi syndrome exhibit hypogonadotropic hypogonadism, there is variability regarding sexual maturation, with precocious puberty occurring in rare cases. Our aim is to elaborate a thorough review of Prader-Willi patients with central precocious puberty, in order to raise awareness of such cases and to enhance our knowledge regarding the diagnosis and prompt treatment of this particular PWS patients.

Prader-Willi syndrome (PWS, OMIM176270) is a rare genetic disorder with recognizable dysmorphic features and multisystemic consequences such as endocrine, neurocognitive and metabolic ones (1, 2). Although described in 1956 for the first time by Swiss endocrinologists Prader, Labhart and Willi (1), based on clinical aspects, genetic confirmation was possible only since 1980, when high resolution chromosome analysis led to the discovery of the chromosomal deletion of 15q11-g13 (3–5). Most PWS patients display a paternal microdeletion of the long arm of chromosome 15 (70%), whereas 20-35% have maternal uniparental disomy 15 (mUPD), and even fewer patients have an imprinting center defect (ICD) or an unbalanced translocation (0,1%) (6). With an estimated prevalence of 1 in 10.000-30.000 live births, Prader-Willi syndrome represents the most common genetic cause of obesity (7–9) and the first recognized disorder of human genetic imprinting (10). PWS displays great clinical variability throughout life (1), ranging from hypotonia and failure to thrive during infancy, to morbid obesity, dysmorphic features, short stature and behavioral problems such as hyperphagia and aggressive behavior (11). Patients require multidisciplinary approach, including close endocrinologic follow-up throughout their lives (12) given the hypothalamic-pituitary dysfunction that characterizes these patients. This disfunction leads in turn to multiple endocrinopathies, the most common ones being growth hormone deficiency (GHD), hypogonadism and hypothyroidism (12, 13). Genital anomalies are common in both female and male PWS patients and are represented by pubertal development disorders (14). Hypogonadism represents a major clinical diagnostic criteria of PWS, according to Holm and Cassidy (13). In Prader-Willi syndrome puberty is most often delayed and incomplete. While PWS male patients usually present cryptorchidism and remain in a Tanner genital stage II or III (14), most female PWS patients have amenorrhea or oligomenorrhea, with only a few undergoing spontaneous menarche (15). However, exceptional cases leading up to pregnancy have been described (6), isolated premature pubarche is reported in 14% of cases (1). Despite most PWS patients having hypogonadism, a few cases of central precocious puberty (CPP) have been reported (16). Our aim is to elaborate a thorough review of Prader-Willi patients that display central precocious puberty, in order to raise awareness of such cases and to enhance our knowledge regarding the diagnosis and prompt treatment of this particular PWS patients.

• The literature review was based on the available papers written in English published in the electronic databases PubMed and Embase database between 1979 and January 2023. • The search criteria used in the Medical Subject Headings (MeSH) included te following terms: “Prader-Willi” [All Fields] AND (“precocious puberty)”[MeSH Terms] • RCTs reported as literature reviews, case reports and conference abstracts with relevant outcome data were included in the review. Articles and abstracts regarding only premature adrenarche, or cases without genetic confirmation were excluded from the study. • Duplicates were removed.

The following data were collected from each article/abstract if available: age and gender, genetic background, Tanner Pubertal Stage, GnRH stimulation test, determination of basal and peak Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) serum levels, Testosterone, bone age, ultrasound of genitalia, stabilization or regression of Tanner Pubertal Stage under GnRH (gonadotropin releasing hormone) treatment according to dose and duration. Patients were included if they fulfilled diagnostic criteria for CPP (i.e. age at pubertal onset, bone age, Tanner stage, significant value of LH, FSH and Testosterone GnRH stimulation test).

We sought to summarize the following outcome measures from the reviewed articles: ▪ suppression of physical signs of puberty: breast development in females, testicular volume in males, genital development – based on modified Tanner staging ▪ incremental growth rate: cm/year ▪ suppression of GnRHa – stimulated LH: peak LH value ▪ incremental change in bone age We identified a total of 22 children with CPP and genetically confirmed Prader-Willi syndrome mostly in case reports and abstracts, summarizing 13 children from case reports and case studies [13-22] and 9 children from Embase indexed abstracts [23-27]. There were 13 (59%) male patients and 9 (41%) female cases, with mean age at CPP onset of 7,64 +/- 1,01 years (5 – 9 years). At diagnosis they were Tanner stage II-III, mean basal LH was 1,43 +/- 1,46 UI/L (0,3 – 4,6 UI/L), and mean stimulated peak LH was 13,67 +/- 6,45 UI/L (4,6 – 29,7 UI/L). Mean basal FSH was 1,43 +/- 1,46 UI/L (0,3 – 4,6 UI/L) stimulated peak FSH was 13,67 +/- 6,45 UI/L (4,6 – 29,7 UI/L). Auxological parameters and response to GnRH of the PWS patients with precocious puberty are displayed below in Tables 1 , 2 .

Pubertal timing is a complex process, with genetic, epigenetic, endocrine, metabolic and lifestyle factors playing a role in acquiring secondary sexual characteristics, gonadal maturation and progression of linear growth (28, 29). It normally coincides with the pulsatile release of GnRH from the hypothalamic neurons (30). Normal pulsatile GnRH secretion is initially observed during fetal and neonatal periods (31, 32), suppressed during childhood, only to resume at the age of puberty, under action of Kisspeptin (33). The first symptoms of precocious puberty are regarded in girls as onset of breast development before the age of 8 years, and in boys as testicular enlargement ≥ 4 ml before the age of 9 years (29), in accordance with the mean age at CPP onset in the reviewed cases (7,64 +/- 1,01 years). The underlying mechanism can be central (GnRH- dependent) or peripheral (GnRH-independent). In Prader-Willi cases associated with precocious puberty only central precocious puberty has been described (13–27).

The most sensitive biomarker in CPP is LH, as it is untraceable before the first stages of puberty (34). Therefore determining plasma LH after exogenous GnRH or LHRH stimulation represents the reference test for diagnosing central precocious puberty (35–38). Yet peak cut-off values beyond which puberty is activated remain controversial (35, 36, 38). Values between 5 and 10 IU/L are considered acceptable cut-off points, using Chemiluminescent immunoassay (36, 38). Further assessment includes assessment of bone age (usually advanced as compared to chronological age), pelvic or testicular ultrasonography (to aid in identifying signs of peripheral precocious puberty) and brain magnetic resonance imaging in order to evaluate the hypothalamus and pituitary glands, and to exclude other brain anomalies (39). 9 cases describe imagistic evaluation through cerebral MRI, out of which 3 had abnormalities: one male patient with ischemic cerebral lesions, one with pituitary hypoplasia and one with a small pineal cyst. It can be argued that such cerebral lesions account in part for the precocious puberal onset, but additional causes related to this patients remain obscure.

Premature activation of the hypothalamic–pituitary–gonadal (HPG) axis can have several repercussions in children and adolescents, from height deficit caused by premature fusion of epiphyses through accelerated bone maturation, to premature sexual maturation that cause body changes (34, 40). Accumulating evidence points out to the absolute or relative growth hormone deficiency in most cases of PWS patients (41–48), according to standard testing protocols (49). As such, adult height prognosis is additionally compromised in children with Prader-Willi syndrome that exhibit central precocious puberty. This reinforces the interest of detecting any central precocious puberty in Prader-Willi patients. Central precocious puberty also occurs in other diseases that associate hypopituitarism, among which lesions of the central nervous system, such as intracranial malignancies and cranial radiotherapy (50–53), severe head injury (53), arachnoid cyst and septo-optic dysplasia (54–58). Other possible situations involve genetic causes such as, combined pituitary hormone deficiency due to POU1F1 gene mutation (59, 60), Kabuki syndrome (61, 62), Williams–Beuren syndrome (63, 64), Mayer-Rokitansky-Kuster-Hauser syndrome (65) and developmental defect of the hypothalamic–pituitary area (66). The possible common etiological mechanisms in both situations should also be the subject of further studies, as the underlying mechanism of remains unclear (59). Also, there is increased risk for metabolic comorbidities such as obesity, type 2 diabetes and for cardiovascular events (34, 67, 68). As such, there is increased need for prompt treatment. GnRH analogues are the cornerstone of treatment, and they are administered either intramuscular (1 administration every 28 days) or by subcutaneous implant (69). They have been used effectively in cases of CPP, reducing plasma gonadotrophins, gonadal steroids and peptides (34, 70). Adequate suppression of gonadotrophins can be seen after 3 – 4 months of treatment (71). Future therapeutic options that are being evaluated as an alternative option include newer kisspeptin and neurokinin B antagonists (69, 72, 73). Clinical trials investigating the short term efficacy of GnRH analogs confirm the fact that this treatment is well tolerated and safe (71, 74–76). Also, case reports regarding PWS patients with central precocious puberty highlight the possible benefit of combined therapy (gonadotropin-releasing hormone agonist and recombinant human growth hormone) on final height, while restoring appropriate pubertal progression (16, 17).

Due to the exceedingly rare cases of PWS patients with precocious puberty, reviewed cases stemmed from case reports and Embase registered conference abstracts. Yet, it is our belief that such cases promote a better understanding of the variety of sexual maturation disorders in PWS patients.

Although most patients with Prader-Willi syndrome exhibit hypogonadotropic hypogonadism, there is variability regarding sexual maturation, with precocious puberty occurring in rare cases. Recent years have brought major improvement in scientific knowledge regarding PWS, but there is still a need for further studies to assess the pathophysiology implicated in timing and progression of pubertal onset (15), and to implement clinical guidelines (12). GnRH agonist therapy seems to be efficient and safe in such cases, although long term follow-up is of need to better address the issue (71, 74–76).

DMN, ACS identified potential papers, D-MN and ACS wrote original draft, D-MN, A-CS, NM, IJ, A-IM and LV analyzed selected papers, and took the lead in writing the manuscript. OM supervised the project and recommended changes. All authors contributed to the article and approved the submitted version.